Last edition
News about "Tevimbra"
BeOne Medicines reports positive Phase 3 results showing improved overall survival with Ziihera-based regimens in patients with HER2-positive gastroesophageal adenocarcinoma.
Tevimbra | 01/09/2026 | By News Bureau
Tevimbra, Ziihera and chemotherapy combination improves overall and progression-free survival in first-line treatment of unresectable or metastatic HER2-positive gastroesophageal adenocarcinoma.
Tevimbra | 27/08/2026 | By News Bureau
US FDA Approves Ziihera for First-Line HER2+ Gastroesophageal Cancer
The US Food and Drug Administration (FDA) approves Ziihera plus tislelizumab and chemotherapy for first-line treatment of HER2+ advanced gastroesophageal adenocarcinoma regardless of PD-L1 status.
Tevimbra | 26/08/2026 | By News Bureau
U.S. Food and Drug Administration grants Priority Review and Breakthrough Therapy status to combination therapy showing significant survival benefits in advanced HER2-positive gastric and esophageal cancers.
Tevimbra | 01/05/2026 | By News Bureau | 123
U.S. Food and Drug Administration accepts sBLA for Ziihera with Priority Review, backed by Phase III data showing improved outcomes in HER2-positive advanced gastric and gastroesophageal cancers.
Tevimbra | 29/04/2026 | By News Bureau | 210
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy